Guanfacine to Treat Borderline Personality Disorder
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2006 by Bronx VA Medical Center.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Icahn School of Medicine at Mount Sinai
Information provided by:
Bronx VA Medical Center
ClinicalTrials.gov Identifier:
NCT00358969
First received: July 31, 2006
Last updated: NA
Last verified: July 2006
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is designed to investigate whether guanfacine (Tenex) is an effective treatment for borderline personality disorder (BPD), an illness often characterized by unstable mood and impulsive aggression. Guanfacine stimulates activity in the front portion of the brain, a region associated with attention and the control of behavior. We believe that guanfacine may improve symptoms of BPD by improving attention and aiding regulation of behavior.
| Condition | Intervention |
|---|---|
|
Borderline Personality Disorder |
Drug: guanfacine (Tenex) |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Guanfacine in the Treatment of Borderline Personality Disorder |
Resource links provided by NLM:
Further study details as provided by Bronx VA Medical Center:
Primary Outcome Measures:
- measures of impulsive aggression
- measures of affective disturbance
- measures of social and occupational functioning
- measures of overall clinical status
| Study Start Date: | July 2006 |
This is an 8-week treatment study designed to test whether guanfacine is an effective treatment for borderline personality disorder (BPD). Prior to taking the study medication, subjects will have medical and psychiatric evaluations, complete self-report questionnaires, do a functional MRI scan, and complete a set of cognitive tests. While taking the study medication, participants will meet weekly with a study doctor and be administered interviews and questionnaires. At the end of the 8-week trial, participants will be asked to repeat the MRI scan and cognitive tests.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria: This study includes men and women between the ages of 18 and 55 who meet criteria for borderline personality disorder with impulsive aggression.
Exclusion Criteria: Subjects must not currently be taking any psychiatric medications. Subjects must not meet criteria for current substance dependence, current major depression, bipolar disorder, or schizophrenia-spectrum disorders.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00358969
Please refer to this study by its ClinicalTrials.gov identifier: NCT00358969
Contacts
| Contact: Emily Hart | (212) 241-4459 | mpgroup@mssm.edu | |
| Contact: David Meyerson | (212) 241-9734 | david.meyerson@mssm.edu |
Locations
| United States, New York | |
| Mount Sinai Hospital - Mood & Personality Research Group | Recruiting |
| New York, New York, United States, 10029 | |
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Investigators
| Principal Investigator: | Antonia S. New, M.D. | Icahn School of Medicine at Mount Sinai |
More Information
| ClinicalTrials.gov Identifier: | NCT00358969 History of Changes |
| Other Study ID Numbers: | GCO 06-0518 |
| Study First Received: | July 31, 2006 |
| Last Updated: | July 31, 2006 |
| Health Authority: | United States: Federal Government |
Keywords provided by Bronx VA Medical Center:
|
borderline personality disorder guanfacine impulsivity aggression affective instability |
Additional relevant MeSH terms:
|
Disease Personality Disorders Borderline Personality Disorder Pathologic Processes Mental Disorders Guanfacine Antihypertensive Agents |
Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on September 28, 2016